NCT02096601View on ClinicalTrials.gov

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 11, 2014

Primary Completion Date

March 15, 2015

Study Completion Date

March 15, 2015

Conditions
Parkinson's Disease
Interventions
DRUG

LD/CD SC solution

Levodopa/carbidopa SC solution

DRUG

Entacapone

Entacapone 200 mg oral tablet

Trial Locations (2)

Unknown

Hadassah Medical Center, Jerusalem

Tel Aviv Medical Center, Tel Aviv

Sponsors

Lead Sponsor

NeuroDerm Ltd.
All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

NeuroDerm Ltd.

INDUSTRY

NCT02096601 - A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter